#London #United Kingdom #Leadership Team #Ottimo Pharma #Jankistomig

Ottimo Pharma Strengthens Leadership for Innovative Cancer Treatment

Ottimo Pharma, a cutting-edge biotech firm, has recently made notable appointments to its leadership team that aim to accelerate the clinical development of its lead candidate, Jankistomig. This innovative therapy is designed to target PD1 and VEGFR2 in a dual-pathway approach, setting it apart in the ever-evolving landscape of cancer treatments.

In a strategic move to enhance its expertise, Robert Tighe has been appointed as the Senior Vice President of Preclinical and Translational Sciences. Tighe brings with him over two decades of extensive experience in biopharmaceutical research, particularly in the realms of preclinical and translational development focused on immuno-oncology. His most recent role as Chief Scientific Officer at Ankyra Therapeutics saw him lead the development of a novel immunotherapy platform aimed at targeted drug delivery within tumors. Tighe's successful track record includes the translation of six investigational new drug applications into clinical settings, showcasing his capability to drive innovative treatments into real-world applications.

Joining Tighe is Katherine Bell-McGuinn, M.D., Ph.D., who steps in as the Senior Vice President of Clinical Development. With a wealth of experience in oncology, Bell-McGuinn has held senior positions at leading biopharma companies, including Chief Medical Officer at 858 Therapeutics and a leadership role at AbbVie. At AbbVie, she played a crucial role in orchestrating early-stage oncology programs and successfully transitioned numerous therapies from preclinical to clinical trials. Her expertise aligns perfectly with Ottimo's mission, as she is poised to guide the clinical development strategy and ensure effective execution of clinical trials for Jankistomig.

The CEO of Ottimo, David Epstein, expressed his enthusiasm regarding the new appointments, highlighting the immense value that Tighe and Bell-McGuinn will bring to the organization. Their combined expertise in immuno-oncology and clinical development is expected to significantly enhance the trajectory of Jankistomig, a unique PD1/VEGFR2 dual pathway antibody that is being positioned to enter clinical trials following its anticipated IND filing in late 2025.

The therapeutic design of Jankistomig is particularly noteworthy, as it operates independently of circulating VEGF levels, which is a considerable advantage over traditional treatments that often hinder efficacy due to varying VEGF levels in patients. As Bell-McGuinn stated, this unique mode of action and the therapy's differentiated profile could potentially revolutionize treatment outcomes for patients with solid tumors. The combination of a biparatopic mechanism and carefully engineered dual-targeting capabilities signifies a monumental stride towards more effective cancer therapies.

Ottimo Pharma, which emerged from stealth just over a year ago, is committed to transforming the landscape of cancer treatment through innovative dual pathway antibodies that can significantly improve patient outcomes and extend lives. With broad support from a global syndicate of life science investors, including prominent names like Medicxi and OrbiMed, the company is well-positioned to implement its ambitious plans.

In summary, by fortifying its leadership team with accomplished executives like Robert Tighe and Katherine Bell-McGuinn, Ottimo Pharma is enhancing its capacity to develop pioneering therapies that could redefine cancer treatment paradigms. The journey ahead promises excitement as the company gears up for critical milestones leading to the clinical introduction of Jankistomig, which embodies the hope and determination of advancing oncological care.